Botanix Pharmaceuticals Ltd
BOT
Company Profile
Business description
Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1204 - Atopic Dermatitis, and BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is Derived from Australia.
Contact
41 - 47 Colin Street
Suite 3
West PerthWA6005
AUST: +61 865552945
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
1
Stocks News & Analysis
stocks
Stellar growth from ASX retailer but markets still too optimistic
This Australian success story looks set to face profit margin compression from the scariest of competitors.
stocks
How to focus on the right things this reporting season
For individual investors, it is important to frame earnings season revelations in a long-term way.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,150.30 | 32.70 | 0.36% |
| CAC 40 | 7,753.42 | 54.90 | 0.71% |
| DAX 40 | 24,024.78 | 56.56 | -0.23% |
| Dow JONES (US) | 44,455.38 | 480.29 | 1.09% |
| FTSE 100 | 9,147.81 | 18.10 | 0.20% |
| HKSE | 24,969.68 | 62.87 | 0.25% |
| NASDAQ | 21,652.36 | 266.96 | 1.25% |
| Nikkei 225 | 42,718.17 | 897.69 | 2.15% |
| NZX 50 Index | 12,759.68 | 152.18 | -1.18% |
| S&P 500 | 6,438.78 | 65.33 | 1.03% |
| S&P/ASX 200 | 8,880.80 | 36.00 | 0.41% |
| SSE Composite Index | 3,665.92 | 18.37 | 0.50% |